Log in

NYSE:MEDMedifast Stock Price, Forecast & News

+0.98 (+0.96 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $103.32
50-Day Range
MA: $81.94
52-Week Range
Now: $103.32
Volume218,613 shs
Average Volume298,592 shs
Market Capitalization$1.22 billion
P/E Ratio16.43
Dividend Yield4.42%
Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, franchise weight loss clinics, and direct consumer marketing. The company was founded in 1980 and is headquartered in Baltimore, Maryland.
Read More
Medifast logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.0Community Rank: 2.4Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars

Industry, Sector and Symbol

Industry Miscellaneous food preparations & kindred products
Sub-IndustryPersonal Products
SectorConsumer Staples



Sales & Book Value

Annual Sales$713.67 million
Cash Flow$6.72 per share
Book Value$9.03 per share


Net Income$77.92 million


Market Cap$1.22 billion
Next Earnings Date8/6/2020 (Estimated)

Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.

Medifast (NYSE:MED) Frequently Asked Questions

How has Medifast's stock been impacted by COVID-19 (Coronavirus)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 46.7% and is now trading at $103.32. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Medifast?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Medifast.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Medifast.

How were Medifast's earnings last quarter?

Medifast Inc (NYSE:MED) issued its quarterly earnings results on Tuesday, May, 5th. The specialty retailer reported $1.93 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.33 by $0.60. The specialty retailer earned $178.46 million during the quarter, compared to the consensus estimate of $161.90 million. Medifast had a net margin of 10.41% and a return on equity of 65.66%. View Medifast's earnings history.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast declared a quarterly dividend on Thursday, March 19th. Investors of record on Tuesday, March 31st will be paid a dividend of $1.13 per share on Wednesday, May 6th. This represents a $4.52 annualized dividend and a dividend yield of 4.37%. The ex-dividend date of this dividend is Monday, March 30th. View Medifast's dividend history.

What price target have analysts set for MED?

3 brokerages have issued 12 month price targets for Medifast's shares. Their forecasts range from $86.00 to $90.00. On average, they anticipate Medifast's share price to reach $88.00 in the next twelve months. This suggests that the stock has a possible downside of 14.8%. View analysts' price targets for Medifast.

Has Medifast been receiving favorable news coverage?

Media headlines about MED stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Medifast earned a news impact score of 3.5 on InfoTrie's scale. They also assigned media headlines about the specialty retailer a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutMedifast.

Who are some of Medifast's key competitors?

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), Home Depot (HD), Boeing (BA), Mastercard (MA), Micron Technology (MU), AbbVie (ABBV), Adobe (ADBE), Paypal (PYPL) and Baidu (BIDU).

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Mr. Daniel R. Chard, CEO & Director (Age 54)
  • Mr. Timothy G. Robinson CPA, CPA, Chief Financial Officer (Age 57)
  • Mr. William Baker IV, Exec. VP of Information Technology (Age 47)
  • Mr. Nicholas Johnson, Exec. VP of Coach Success Market Pres of OPTAVIA USA (Age 39)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 48)

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.05%), Rice Hall James & Associates LLC (3.57%), Rice Hall James & Associates LLC (3.57%), State Street Corp (2.96%), Pictet Asset Management Ltd. (2.25%) and Bank of New York Mellon Corp (2.02%). Company insiders that own Medifast stock include Carl E Sassano, Constance J Hallquist, Daniel R Chard, Jeffrey J Brown, Michael A Hoer, Michael C Macdonald and Scott Schlackman. View institutional ownership trends for Medifast.

Which major investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., BlackRock Inc., Acadian Asset Management LLC, BNP Paribas Arbitrage SA, Morgan Stanley, Morgan Stanley, Parametric Portfolio Associates LLC, and Engine Capital Management LP. View insider buying and selling activity for Medifast.

Which major investors are buying Medifast stock?

MED stock was acquired by a variety of institutional investors in the last quarter, including UBS Group AG, Schroder Investment Management Group, Federated Hermes Inc., Robeco Institutional Asset Management B.V., Deutsche Bank AG, Nuveen Asset Management LLC, Bridge City Capital LLC, and State Street Corp. Company insiders that have bought Medifast stock in the last two years include Daniel R Chard, Jeffrey J Brown, and Michael A Hoer. View insider buying and selling activity for Medifast.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $103.32.

How big of a company is Medifast?

Medifast has a market capitalization of $1.22 billion and generates $713.67 million in revenue each year. The specialty retailer earns $77.92 million in net income (profit) each year or $5.96 on an earnings per share basis. Medifast employs 420 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.